Immunovant Stock Drops After Clinical Trial Fails to Meet Primary Endpoint

Immunovant's (NASDAQ: IMVT) stock price declined about 6% on September 23, 2026, hitting a low not seen in over three months. The drop occurred after the company disclosed that its proof-of-concept study for IMVT-1402 in cutaneous lupus erythematosus did not meet its prespecified primary endpoint. Consequently, Immunovant announced the discontinuation of its cutaneous lupus program.

The stock's decline began before the market opened. Following the disclosure, shares moved lower, with reports indicating the stock reached its lowest level in over three months. In the days prior, the stock was trading around $36.95, with a market capitalization of approximately $7.63 billion, as investor attention was focused on upcoming clinical data. IMVT-1402 had been identified as the company's lead development program.

Investors who incurred losses due to the stock's decline on September 23 are being notified of a pending investigation into potential securities law violations. The investigation, led by SueWallSt, aims to determine if Immunovant made misleading statements regarding the clinical prospects of IMVT-1402, its lead development program.

Levi & Korsinsky LLP, the law firm behind SueWallSt, specializes in securities litigation and has a history of recovering significant amounts for shareholders. The firm is examining whether Immunovant's public statements about the clinical outcomes of IMVT-1402 were materially false or misleading. Investors who experienced losses may be eligible for a no-cost review of their potential claims.